The US FDA has approved Moderna's new COVID-19 vaccine, mNEXSPIKE, amidst emerging coronavirus variants. It is approved for ...

Today, the World Health Organization (WHO) published its first-ever position paper on immunization products to protect ...

Patients with respiratory syncytial virus (RSV) hospitalization have increased odds of any acute cardiovascular event ...

Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.

The State Government has extended its free RSV immunisation programme for babies and young children, as WA braces for a surge ...

Universal immunisation with nirsevimab significantly reduces hospitalizations and paediatric intensive care admissions for ...

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Citing concerns about mRNA technology, the Trump administration has pulled funding for a vaccine, even though Moderna says it ...

A statewide immunization program for infants against respiratory syncytial virus (RSV), which began in 2024, has already ...